Augmented post–remission therapy for a minimal residual disease–defined high–risk subgroup of children and young people with clinical standard–risk and intermediate–risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest